Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...

The CHMP’s recommendation is based on results from the MANDARA phase 3 trial, which compared efficacy and safety of benralizumab vs mepolizumab, the only approved treatment for EGPA, in patients ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

This study aimed to investigate the safety of mepolizumab by analyzing the pharmacovigilance database of the US Food and Drug Administration. Methods: The AE signals associated with mepolizumab from ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated ...

Norway's own Jens Stoltenberg, the former highly acclaimed NATO boss, went on national TV in his homeland Wednesday night and reassured Norwegians nervous over the future of the defense alliance.

GlaxoSmithKline has asked the US regulator to expand the licence of its injected lung drug mepolizumab, to include chronic obstructive pulmonary disease (COPD). Under the brand name Nucala ...